Amphastar Pharmaceuticals, Inc.
AMPH
$25.42
$0.763.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.83% | 18.80% | 20.16% | 19.01% | 19.16% |
| Total Other Revenue | -97.16% | -92.43% | -62.56% | 46.56% | -- |
| Total Revenue | 1.37% | 8.05% | 13.59% | 20.33% | 31.80% |
| Cost of Revenue | 12.15% | 17.10% | 23.24% | 24.86% | 23.35% |
| Gross Profit | -7.56% | 0.44% | 5.66% | 16.57% | 39.74% |
| SG&A Expenses | 12.62% | 14.72% | 17.57% | 24.28% | 21.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.01% | 15.35% | 18.40% | 21.91% | 18.73% |
| Operating Income | -20.97% | -7.97% | 2.87% | 16.74% | 71.44% |
| Income Before Tax | -19.73% | -6.06% | 11.70% | 9.62% | 56.39% |
| Income Tax Expenses | -22.73% | 6.56% | -6.79% | -17.72% | 30.14% |
| Earnings from Continuing Operations | -19.10% | -8.44% | 15.98% | 16.58% | 63.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.10% | -8.44% | 15.98% | 16.58% | 63.34% |
| EBIT | -20.97% | -7.97% | 2.87% | 16.74% | 71.44% |
| EBITDA | -15.89% | -3.04% | 8.69% | 23.91% | 76.42% |
| EPS Basic | -18.10% | -8.46% | 15.72% | 16.54% | 62.96% |
| Normalized Basic EPS | -18.66% | -6.07% | 9.67% | 7.81% | 52.75% |
| EPS Diluted | -14.98% | -4.84% | 18.13% | 17.86% | 61.53% |
| Normalized Diluted EPS | -15.50% | -2.55% | 12.21% | 8.67% | 51.04% |
| Average Basic Shares Outstanding | -1.34% | -0.07% | 0.34% | 0.15% | 0.09% |
| Average Diluted Shares Outstanding | -5.10% | -3.73% | -1.78% | -0.37% | 1.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |